Aktie A3DMB5GSK PLC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen GSK plc

Aktien

A3DMB5

GB00BN7SWP63

GSK

Pharmazeutika

Verzögert London S.E.
Andere Börsenplätze
 17:35:04 17.04.2025 		% 5 Tage % 1. Jan.
1.336,50 GBX -0,67 % Intraday Chart für GSK plc +4,82 % -0,74 %
17.04. GSK gibt bekannt, dass Health Canada die erweiterte Indikation für Jemperli genehmigt hat MT
17.04. GSK gibt bekannt, dass Health Canada die Zulassung für Jemperli Plus Chemotherapie erweitert RE

Andere Sprachen

Suchen
Ergebnisse ansehen
GSK Says Health Canada Approves Expanded Jemperli Indication
17.04.
GSK Says Health Canada Expands Jemperli Plus Chemotherapy Approval
17.04.
GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency
17.04.
Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101
17.04.
GSK Gets UK Approval for Blenrep Combinations in Multiple Myeloma
17.04.
GSK receives approval from UK MHRA for Blenrep combination
17.04.
GSK Gets U.K. Approval for Blood Cancer Drug Comeback
17.04.
UK approves combination therapies of GSK's blood cancer drug Blenrep
17.04.
GSK : Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
17.04.
GSK says Blenrep licensed by UK MHRA
17.04.
Global markets live: Nvidia, Amex, GSK, TSMC, Rio Tinto…
17.04.
Alector Announces Completion Of Enrollment In The Progress-Ad Phase 2 Clinical Trial Of Al101/Gsk4527226 In Individuals With Early Alzheimer'S Disease
17.04.
GSK: CDC green light for Penmenvy vaccine in the US
17.04.
GSK gets US advisory panel backing for RSV and Meningitis vaccines
17.04.
GSK's Meningococcal Vaccine Wins Recommendation from US CDC Panel
17.04.
GSK's RSV Vaccine Arexvy Wins US Panel Backing for Expanded Use
17.04.
GSK Gains Positive U.S. Recommendations for Meningitis, RSV Vaccines
17.04.
GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
17.04.
GSK Receives Positive Recommendation from US Advisory Committee for Arexvy in RSV Patients Aged 50-59
17.04.
GSK Says CDC Panel Recommends Penmenvy for Adolescent Meningococcal Vaccination
16.04.
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
16.04.
US CDC advisers recommend lowering the age for RSV shots to 50-59 years
16.04.
US CDC advisers recommend lowering the age for RSV shots to 50-59 years
16.04.
GSK Receives CDC Recommendation for 5-in-1 Meningococcal Vaccine
16.04.
GSK : Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
16.04.
Keine Ergebnisse zu dieser Suche
Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DMB5 Aktie
  4. Nachrichten GSK plc
  5. Andere Sprachen
Vereinigte Staaten

MarketScreener is also available in this country: United States.

Switch edition
Bei der aktuellen länderspezifischen Edition bleiben